Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration

FREMONT, Calif., Sept. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Ardelyx, Inc. (Nasdaq : ARDX ), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting U.S. marketing authoriz... Biopharmaceuticals, Gastroenterology Ardelyx, tenapanor, IBS-C, irritable bowel syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news